ATE139447T1 - Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen - Google Patents

Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen

Info

Publication number
ATE139447T1
ATE139447T1 AT92901246T AT92901246T ATE139447T1 AT E139447 T1 ATE139447 T1 AT E139447T1 AT 92901246 T AT92901246 T AT 92901246T AT 92901246 T AT92901246 T AT 92901246T AT E139447 T1 ATE139447 T1 AT E139447T1
Authority
AT
Austria
Prior art keywords
enhancing
agent
effect
pct
multiple drugs
Prior art date
Application number
AT92901246T
Other languages
English (en)
Inventor
Ann Christie King
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909027367A external-priority patent/GB9027367D0/en
Priority claimed from GB909027402A external-priority patent/GB9027402D0/en
Priority claimed from GB909027358A external-priority patent/GB9027358D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE139447T1 publication Critical patent/ATE139447T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92901246T 1990-12-18 1991-12-17 Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen ATE139447T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909027367A GB9027367D0 (en) 1990-12-18 1990-12-18 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB909027402A GB9027402D0 (en) 1990-12-18 1990-12-18 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB909027358A GB9027358D0 (en) 1990-12-18 1990-12-18 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance

Publications (1)

Publication Number Publication Date
ATE139447T1 true ATE139447T1 (de) 1996-07-15

Family

ID=27265406

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92901246T ATE139447T1 (de) 1990-12-18 1991-12-17 Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen

Country Status (8)

Country Link
US (1) US5416091A (de)
EP (1) EP0563134B1 (de)
JP (1) JPH06504772A (de)
AT (1) ATE139447T1 (de)
AU (1) AU665341B2 (de)
CA (1) CA2098198A1 (de)
DE (1) DE69120430D1 (de)
WO (1) WO1992011034A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
DE69429440T2 (de) * 1993-10-15 2002-08-08 Schering Corp., Kenilworth Tricyclische sulfonamide-derivate zur inhibierung der g-protein funktion und fur die bekandlung von proliferativen erkrantungen
US5661152A (en) * 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
ES2164716T3 (es) * 1993-10-15 2002-03-01 Schering Corp Compuestos triciclicos de carbamato utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
US6365588B1 (en) 1993-10-15 2002-04-02 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5574173A (en) * 1993-12-06 1996-11-12 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5464840A (en) * 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5516655A (en) * 1994-04-20 1996-05-14 Eli Lilly And Company Multiple drug resistance gene of Aureobasidium pullulans
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
US5705352A (en) * 1995-02-27 1998-01-06 Eli Lilly And Company Multiple drug resistance gene of Aspergillus fumigatus
US5773214A (en) * 1995-02-27 1998-06-30 Eli Lilly And Company Multiple drug resistance gene of aspergillus flavus
US5700806A (en) * 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5684013A (en) * 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5891872A (en) * 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
IL117797A0 (en) * 1995-04-07 1996-08-04 Pharmacopeia Inc Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) * 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
CZ9904244A3 (cs) * 1997-05-27 2001-10-17 Baker Norton Pharmaceuticals, Inc. Pouľití taxanů, jejich derivátů, analogů nebo předléků pro přípravu farmaceutického prostředku pro perorální podávání
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US6479481B1 (en) * 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
ATE317697T1 (de) * 1997-12-22 2006-03-15 Schering Corp Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
JP2002512029A (ja) 1998-04-21 2002-04-23 マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー．ファウ． ヒトｋ＋イオンチャンネルおよびその治療的適用
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
WO2001045668A2 (en) 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
CN1479630A (zh) 2000-10-05 2004-03-03 Q 诱导癌细胞死亡和肿瘤消退的方法
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) * 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6703400B2 (en) 2001-02-23 2004-03-09 Schering Corporation Methods for treating multidrug resistance
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
EP2161023A3 (de) * 2007-04-13 2010-12-29 Southern Research Institute Anti-Angiogenese-Mittel und Anwendungsverfahren dafür

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines

Also Published As

Publication number Publication date
EP0563134B1 (de) 1996-06-19
CA2098198A1 (en) 1992-06-18
EP0563134A1 (de) 1993-10-06
WO1992011034A1 (en) 1992-07-09
US5416091A (en) 1995-05-16
AU9062691A (en) 1992-07-22
DE69120430D1 (de) 1996-07-25
JPH06504772A (ja) 1994-06-02
AU665341B2 (en) 1996-01-04

Similar Documents

Publication Publication Date Title
ATE139447T1 (de) Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE123943T1 (de) Mittel zur behandlung und vorbeugung von bauchentzündungen, die als wirkstoff zink-l- carnosin-salze oder -komplexe enthalten.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
MY131911A (en) N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2h-benzopyran or dihydrobenzodioxin) carboxamide derivatives
MX9201621A (es) Aminas heterociclicas utiles en la terapia de asma e inflamacion del tracto respiratorio.
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
DK0790824T3 (da) 2,2-dichloralkancarboxylsyrer, fremgangsmåde til fremstilling deraf, lægemidler indeholdende disse og anvendelse af disse lægemidler til behandling af insulinresistens
DE69637050D1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer
ATE200672T1 (de) Alkoxyalkylcarbamate von imidazo(1,2-a)pyridinen
ATE382061T1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
ATE154235T1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
SE9402880D0 (sv) New peptide derivatives
ZA937147B (en) Heterocyclic amines useful in the therapy of the asthma and of the inflammation of the respiratory tract
DE69330150D1 (de) Pharmazeutische Zusammensetzungen zur transdermalen Verabreichung von Melatonin und/oder seine Analoge
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
DE69400704D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
MX9201288A (es) Metodo de tratamiento.
KR900017599A (ko) 종양 치료용 약학 조성물
SE9401596D0 (sv) New compounds
ATE165509T1 (de) Avermectine und milbemycine zur behandlung von parazitären infektionen beim hund
DE59209069D1 (de) Verwendung von apotransferrin, welches zink- oder kupferionen angelagert hat, zur bekämpfung der toxischen wirkung des endotoxins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties